

Data Sharing Statement

Rosenstock et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk [published online November 9, 2018]. *JAMA*. doi:10.1001/jama.2018.18269

Data

Data available: Yes

Data types: Other (please specify)

Additional Information: Will be made available upon reasonable request in adherence with open sharing practice

How to access data: Data related to the specific manuscript will be made available upon reasonable request in adherence with transparency conventions in medical research and through requests to the corresponding author (juliorosenstock@dallasdiabetes.com). The steering committee of CARMELINA has predeveloped a comprehensive analysis plan and pre-specified numerous analyses, that will subsequently be followed by scientific presentations and publications. The full database will at a later timepoint be made available in adherence with the ratified transparency policy which is detailed here: https://trials.boehringer-ingenelheim.com/transparency_policy.html.

When available: With publication, beginning date: 12-01-2020

Supporting Documents

Document types: None

Additional Information

Who can access the data: Researchers whose proposed use of the data has been approved

Types of analyses: For clinical scientific interpretation and publication

Mechanisms of data availability: After approval from the steering committee and later after approval from the committee that steers the access according to the transparency policy

Any additional restrictions: See datasharing statement